Dr Reddy's wins DCGI approval for Zytorvi in India
In short
Dr Reddy's Laboratories has received DCGI approval for Zytorvi in India. The medicine is for advanced oesophageal squamous cell carcinoma.
This matters because the approval could help the company add a new treatment option. The reporting does not say when the drug will be sold or how much it could earn.
What the reporting says
Dr Reddy's Laboratories received DCGI approval for Zytorvi to treat advanced oesophageal squamous cell carcinoma in India. The available reporting does not state when sales will begin, what pricing will be, or whether any revenue impact has been quantified. The clearance is an important regulatory step for the company, but the commercial outcome remains unknown.
Why it matters
Dr Reddy's Laboratories received DCGI approval for Zytorvi in India for advanced oesophageal squamous cell carcinoma. The approval is a regulatory milestone for the company and could support its oncology portfolio, but the reporting does not state launch timing, pricing or sales impact. No further commercial details are provided in the available summary.